Clinical Trials
13 trialsNCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03155620 2026-06-01
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05554367 2026-05-13
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03526250 2026-04-03
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03446157 2026-03-10
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT07191977 2025-09-25
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma
West China Hospital
Phase 2 Not yet recruiting
NCT01907607 2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2 Completed
NCT01356628 2025-07-28
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Thomas Jefferson University
Phase 2 Completed
NCT03981614 2024-08-22
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05865132 2023-05-18
Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
NCT01037790 2021-03-11
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed